Erasca ERAS
NASDAQ ERAS
$16.15 -0.11 (-0.68%)
As of: Sep 4, 2026 · 12:51 PM EDT

Erasca (ERAS) Other Non Operating Income (2023 - 2026)

Erasca's (ERAS) quarterly Other Non Operating Income came in at $22000.0 in Q1 2026, up 128.95% YoY from $9609.2 in Q1 2025, and up 159.46% on a QoQ basis from -$37000.0 in Q3 2025.

Analysis

Erasca (ERAS) Other Non Operating Income (2023 - 2026) Analysis & Trends

Erasca (ERAS) has 4 years of Other Non Operating Income data on file, last reported at $22000.0 in Q1 2026.

  • Quarterly Other Non Operating Income rose 128.95% year-over-year to $22000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $82000.0 (changed N/A YoY) and the FY2022 annual result came in at -$257000.0, down 181.85% from the prior year.
  • Other Non Operating Income advanced to $22000.0 in Q1 2026, from -$37000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $173000.0 in Q3 2024 to a low of -$76000.0 in Q1 2025.
  • A 4-year average of $6600.0 and a median of -$37000.0 in 2025 frame the typical range for Other Non Operating Income.
  • Annual changes were most pronounced in 2024 — Other Non Operating Income jumped 453.06% — and 2025, when it plunged 121.39%.
  • Tracing ERAS's Other Non Operating Income over 4 years: stood at -$49000.0 in 2023, then jumped by 453.06% to $173000.0 in 2024, then sank by 121.39% to -$37000.0 in 2025, then surged by 159.46% to $22000.0 in 2026.
  • The last three Other Non Operating Income figures came in at $22000.0 (Q1 2026), -$37000.0 (Q3 2025), and -$76000.0 (Q1 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.62 Bn 131.77 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.73 Bn 77.73 Bn 3.93 Bn
3 Argenx Se 63.53 Bn 58.35 Bn 1.37 Bn
4 Moderna 58.23 Bn 53.09 Bn 52.00 Mn
5 Revolution Medicines 44.05 Bn 44.05 Bn -
6 BeOne Medicines 40.03 Bn 34.93 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.50 Bn 32.19 Bn 992.69 Mn
8 Royalty Pharma 28.52 Bn 27.68 Bn -
9 Insmed 27.46 Bn 26.30 Bn 358.27 Mn
10 Erasca 5.03 Bn 5.03 Bn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 22,000.00
Sep 30, 2025 -37,000.00
Mar 31, 2025 -76,000.00
Sep 30, 2024 173,000.00
Sep 30, 2023 -49,000.00